Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

Background This retrospective cohort study assessed benefits and risks of bedaquiline
treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating …

Background The Médecins Sans Frontières Clinic in Mumbai, India, has been providing
concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with …

Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …

Multidrug-resistant (MDR) tuberculosis (TB) has been emerging at an alarming rate over the
last few years. It has been estimated that about 3% of all pediatric TB is MDR, meaning …

Patients with multidrug-resistant (MDR) tuberculosis (TB), in particular those with pre-
extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR)-TB, and those …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) represent
a therapeutic challenge [1]. Two anti-TB agents, bedaquiline and delamanid, have been …

Background The emergence of drug resistance is a major threat to global tuberculosis (TB)
care and control. The World Health Organization (WHO) estimates that up to half a million …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …